AlzeCure initiates clinical trial with ACD856
AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of drug candidates for diseases affecting the central nervous system, with a focus on Alzheimer's disease, announces that it has obtained the necessary approvals from the regulatory authorities and today initiates the first clinical trial with ACD856, the company's leading drug candidate within the NeuroRestore platform.ACD856 is being developed as a new generation of symptom-relieving drugs for the treatment of disorders with cognitive dysfunction, such as Alzheimer’s disease. The first